Pharmacological treatment of cognitive deficits in Alzheimer's disease

Medical Journal of Australia

Volumn 175, Issue 6, 2001, Pages 324-329

  Brodaty, H ^a   Ames, D ^a   Boundy, K L ^a   Hecker, J ^a   Snowdon, J ^a   Storey, E ^a   Yates, M W ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BACOPA MONNIERI EXTRACT; BETA SECRETASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; FOLIC ACID; GALANTAMINE; GAMMA SECRETASE; GINKGO BILOBA EXTRACT; HOMOCYSTEINE; HORMONE; LAZABEMIDE; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; PLANT EXTRACT; RIVASTIGMINE; SABELUZOLE; SELEGILINE; TACRINE; UNCLASSIFIED DRUG; WARFARIN;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ANOREXIA; BEHAVIOR; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HORMONE SUBSTITUTION; HUMAN; LIVER TOXICITY; MALAISE; MEDICAL ASSESSMENT; META ANALYSIS; NONHUMAN; OCCUPATIONAL THERAPY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PROTECTION; REVIEW; SOCIAL SUPPORT; SYMPTOM; TREATMENT OUTCOME; VERTIGO;

EID: 0035903804     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2001.tb143593.x     Document Type: Review

References (50)

1. Practice parameter: Management of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
2. Dietary anti-oxidants and the risk of dementia. The Rotterdam study
3. Statins and the risk of dementia
4. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
5. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease
6. Realistic expectations for the management of Alzheimer's disease
7. Pharmacotherapy of Alzheimer's Disease: Is there a need to redefine treatment success?
8. New rating scale for Alzheimer's disease
9. Clinical global measures of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
10. Donepezil for mild and moderate AD
11. How useful are cholinesterase inhibitors in the treatment of AD? A number needed to treat analysis
12. How to use the evidence: Assessment and application of scientific evidence
13. Anti-dementia drugs
14. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
15. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients
16. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimers disease
17. Rivastigmine for Alzheimer's disease
18. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
19. Systematic review of galantamine for Alzheimer's Disease
20. Tacrine for Alzheimer's disease
21. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
22. Donepezil in Alzheimer's Disease: Eighteen months results from Southampton Memory Clinic
23. Sustained cognitive improvement following treatment of AD with donepezil
24. Metrifonate benefits cognitive, behavioural and global function in AD
25. Cholinesterase inhibitors: A new class of psychotropic compounds
26. A 5-month, randomized, placebo-controlled trial of galantamine in AD
27. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
28. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease
29. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group
30. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract
31. A review of nutrients and botanicals in the integrative management of cognitive dysfunction
32. Use of estrogens for the prevention and treatment of Alzheimer's disease
33. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial
34. The effect of concomitant donepezil and estrogen treatment on the cognitive performance of women with Alzheimer's disease
35. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease
36. Selegiline for Alzheimer's disease
37. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide
38. Homocysteine, Alzheimer's Disease and cognitive function
39. Vascular risk factors for Alzheimer's disease: An epidemiological perspective
40. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
41. 9M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine)
42. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
43. E2020 - The pharmacology of a piperidine cholinesterase inhibitor
44. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
45. An inventory to assess activities of daily living for the clinical trials in Alzheimer's Disease. The Alzheimer's Disease co-operative study
46. Clinical profile of donepezil in the treatment of Alzheimer's disease